Globenewswire·2025-10-01 12:41Core Viewpoint - Elutia Inc. has successfully sold its BioEnvelope business to Boston Scientific for $88 million, allowing the company to focus on its NXT-41x biomatrix aimed at improving breast reconstruction outcomes [1][2][3] Company Overview - Elutia specializes in drug-eluting biomatrix technologies, aiming to enhance compatibility between medical devices and patients [4] - The company is committed to humanizing medicine, enabling patients to thrive without compromise [4] Financial Position - The sale of the BioEnvelope business has significantly strengthened Elutia's financial position, providing the necessary funds to develop and launch the NXT-41x platform [3][6] - Elutia plans to bring NXT-41x to market in the first half of 2027, with expectations of reshaping the breast reconstruction treatment paradigm [3] Market Opportunity - The U.S. market for breast reconstruction procedures is substantial, with over 150,000 procedures performed annually and a total addressable market of approximately $1.5 billion [3][6] - Biologics account for 65% of implant-based costs, indicating a significant opportunity for improved treatment options [3]